Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (1810)	10/26/2015 9:26:03 PM
From: Miljenko Zuanic	Respond to of 3559

RE: PDGF/VEGF Ophthotech completed enrollment in second P3, result in 4Q-16. businesswire.com

To: Miljenko Zuanic who wrote (1810)	10/27/2015 11:42:27 PM
From: Felix B	Read Replies (1) \| Respond to of 3559

They are both secreted proteins no? Hence for better efficancy dual admin would be better. Bispecific would vbe advantageous to very selective isolate two targets (membrane bound) on a single cell for lower toxicity.

To: Miljenko Zuanic who wrote (1810)	11/5/2015 4:03:26 AM
From: nigel bates	Read Replies (1) \| Respond to of 3559

FWIW GHENT, Belgium, 5 November 2015 - Ablynx [Euronext Brussels: ABLX] today announced that its partner Boehringer Ingelheim presented positive in vivo proof-of-mechanism data from the half- life extended bi-specific anti-VEGF/Ang2 Nanobody, at the 8th Euro Global Summit on Cancer Therapy, taking place 3-5 November 2015 in Valencia, Spain. The anti-VEGF/Ang2 Nanobody was discovered and developed as part of the Strategic Alliance between both parties, signed in September 2007. This Nanobody blocks both vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang2), important proteins which are involved in the formation of new blood vessels from pre-existing vessels (angiogenesis), a vital mechanism in the growth of tumours. The data was presented in a poster session by Boehringer Ingelheim on 4 November 2015 at 16.30h CET. Poster title: “Dual targeting of angiogenesis pathways: combined blockade of VEGF and Ang2 signalling”. The results from the pre-clinical study demonstrated that this bi-specific Nanobody potently inhibits VEGF and Ang2 signalling in multiple in vivo cancer models and strongly impairs proliferation and survival of human endothelial cells. In addition, the bi-specific Nanobody showed superior efficacy as compared to inhibition of the individual pathways by the reference monoclonal antibody drugs. The Nanobody was also found to be well tolerated in cynomolgus monkeys. These strong in vivo proof-of-mechanism results support the evaluation of this Nanobody in Phase I clinical studies, which will trigger a milestone payment to Ablynx at study start…